Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in children with cystic fibrosis aged 2–5 years (TIMBERLINE Trial VX21-121-105): a phase 3, open-label study
Elsevier ·
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in children with cystic fibrosis aged 2–5 years (TIMBERLINE Trial VX21-121-105): a phase 3, open-label study. // The Lancet Respiratory Medicine. – URL: https://www.sciencedirect.com/science/article/pii/S2213260026002572?dgcid=rss_sd_all
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in children with cystic fibrosis aged 2–5 years (TIMBERLINE Trial VX21-121-105): a phase 3, open-label study. The Lancet Respiratory Medicine. https://www.sciencedirect.com/science/article/pii/S2213260026002572?dgcid=rss_sd_all
“Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in children with cystic fibrosis aged 2–5 years (TIMBERLINE Trial VX21-121-105): a phase 3, open-label study.” The Lancet Respiratory Medicine.
@article{article88175,
title = {Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in children with cystic fibrosis aged 2–5 years (TIMBERLINE Trial VX21-121-105): a phase 3, open-label study},
journal = {The Lancet Respiratory Medicine},
url = {https://www.sciencedirect.com/science/article/pii/S2213260026002572?dgcid=rss_sd_all}
}